information

MDPI

*Review*

# Prescribing the Future: The Role of Artificial Intelligence in Pharmacy

**Hesham Allam**

Center for Information and Communication Sciences, College of Communication, Information, and Media, Ball State University, Muncie, IN 47304, USA; hesham.allam@bsu.edu

**Abstract:** Integrating artificial intelligence (AI) into pharmacy operations and drug discovery represents a groundbreaking milestone in healthcare, offering unparalleled opportunities to revolutionize medication management, accelerate drug development, and deliver truly personalized patient care. This review examines the pivotal impact of AI in critical domains, including drug discovery and development, drug repurposing, clinical trials, and pharmaceutical productivity enhancement. By significantly reducing human workload, improving precision, and shortening timelines, AI empowers the pharmaceutical industry to achieve ambitious objectives efficiently. This study delves into tools and methodologies enabling AI implementation, addressing ongoing challenges such as data privacy, algorithmic transparency, and ethical considerations while proposing actionable strategies to overcome these barriers. Furthermore, it offers insights into the future of AI in pharmacy, highlighting its potential to foster innovation, enhance efficiency, and improve patient outcomes. This research is grounded in a rigorous methodology, employing advanced data collection techniques. A comprehensive literature review was conducted using platforms such as PubMed, Semantic Scholar, and multidisciplinary databases, with AI-driven algorithms refining the retrieval of relevant and up-to-date studies. Systematic data scoping incorporated diverse perspectives from medical, pharmaceutical, and computer science domains, leveraging natural language processing for trend analysis and thematic content coding to identify patterns, challenges, and emerging applications. Modern visualization tools synthesized the findings into explicit graphical representations, offering a comprehensive view of the key role of AI in shaping the future of pharmacy and healthcare.

**Keywords:** artificial intelligence in pharmacy; machine learning in drug discovery; personalized patient care; medication management; clinical trials automation; drug discovery optimization; AI-driven healthcare; inventory management in pharmacies; medication adherence monitoring; patient-centered care; pharmacists and AI integration



Academic Editor: Neil Vaughan

Received: 7 January 2025
Revised: 30 January 2025
Accepted: 4 February 2025
Published: 11 February 2025

**Citation:** Allam, H. Prescribing the Future: The Role of Artificial Intelligence in Pharmacy. *Information* **2025**, *16*, 131. https://doi.org/10.3390/info16020131



## 1. Introduction

Artificial intelligence (AI) has emerged as an innovative technology across numerous industries, particularly in healthcare, where it holds the potential to revolutionize drug discovery and optimize pharmacy practices. The continuous evolution of AI, fueled by advancements in machine learning and data science, has facilitated the development of innovative solutions to complex challenges in the pharmaceutical sector. AI's adoption is underpinned by the progression of algorithms capable of learning, adapting, automating processes, and performing sophisticated data analysis, paving the way for enhanced decision-making and operational efficiency [1].

Integrating AI into drug discovery rapidly reshapes the pharmaceutical industry, which is driven by substantial financial investments and an expanding market. In 2023, the global AI in drug discovery market was valued at approximately $1.5 billion, with projections indicating a compound annual growth rate (CAGR) of 29.7%, potentially reaching $11.8 billion by 2030 [2]. Similarly, Fortune Business Insights [2] reported a higher market valuation of $3.54 billion in 2023, with expectations expected to grow to $7.94 billion by 2030, reflecting a CAGR of 12.2%. These estimates underscore the significant economic potential of AI technologies in revolutionising drug discovery processes, making it a critical area of focus for innovation and investment in the pharmaceutical sector.

In drug discovery, AI accelerates the identification of therapeutic compounds, offering unparalleled precision and efficiency. Machine learning models accurately predict compound efficacy and safety, streamlining early-stage drug development and enabling drug repurposing. These capabilities significantly reduce the time and costs associated with traditional drug discovery processes while improving the precision of outcomes [3]. Beyond drug discovery, AI transforms pharmacy operations by enhancing medication management and personalising patient care. By integrating AI-driven technologies, pharmacists are equipped with data-driven tools that support precise clinical decision-making. These systems analyse extensive datasets, such as patient medical records and medication histories, to anticipate adverse drug events, optimise dosages, and streamline workflows, ultimately improving patient outcomes [4,5]. This shift towards AI-enhanced pharmacy practices also empowers pharmacists to play a pivotal role in patient safety and therapeutic effectiveness. Despite the groundbreaking potential of AI in drug discovery, its broader applications in pharmacy practice remain underexplored. Key areas such as medication adherence and patient education, which are critical to achieving optimal health outcomes, have not yet received the attention they deserve in current research. Bridging these gaps could unlock a more holistic integration of AI technologies, fostering innovative strategies that care, elevate quality care, and strengthen patient engagement in pharmacy settings.

This research paper will delve into the underutilised potential of AI in pharmacy practice, examining its role in advancing medication adherence, enhancing patient education, and optimising pharmacy operations. By addressing existing gaps in our knowledge, this study aims to provide actionable insights and recommendations for leveraging AI to create a more patient-centred and technology-driven approach to pharmaceutical care. This exploration will highlight case studies and examples where AI has successfully transformed pharmacy practices, illustrating the tangible benefits that can be achieved through its strategic implementation. Through these insights, this paper will also explore challenges and barriers to adopting AI technologies in pharmacy settings, offering solutions to facilitate a smoother integration process for healthcare professionals.

## 2. Methodology

Figure 1 illustrates the systematic process employed to search for, curate, and extract the most recent and relevant literature on AI applications in pharmacy practices. This process ensures a comprehensive and up-to-date review of advancements, challenges, and emerging trends in the field.




**Figure 1.** Methodology stages.

### *2.1. Literature Survey*

We conducted a comprehensive literature review using advanced internet and AI-powered search tools to explore AI's latest advancements, challenges, and applications in drug discovery and pharmacy. These tools included modern search engines, specialised AI-driven literature platforms such as PubMed, Scopus, Web of Science, and Semantic Scholar, and repositories like arXiv and ResearchGate. AI search algorithms were employed to refine the search process, ensuring the retrieval of the most relevant, up-to-date studies published in peer-reviewed journals and preprint archives.

Multidisciplinary Databases

We scoped the data systematically by collecting information from multidisciplinary databases, including medical, pharmaceutical, and computer science domains. This step ensured coverage of diverse perspectives on AI applications in pharmacy. The search included keywords and Boolean operators like AI in drug discovery", "machine learning in pharmacy", "challenges in AI for pharmaceuticals", and "modern AI applications". A systematic approach extracts key information on applications, methodologies, and challenges.

### *2.2. Modern Data Visualization and Synthesis*

The collected data were synthesised and visualized using state-of-the-art tools and AI-driven visualisation platforms. These tools provided a graphical representation of trends, challenges, and key applications, offering a comprehensive view of the Findings.

## 3. Background

### *3.1. The Evolution of Artificial Intelligence in the Pharmaceutical Industry*

The concept of AI is rapidly emerging across various fields, driving pivotal advancements in industries such as manufacturing, finance, and healthcare. This adoption stems from the evolution of algorithms that enable systems to adapt and embrace automation. Algorithms in AI achieve their goals by facilitating learning, decision-making, data processing, and analysis, paving the way for innovative solutions to modern challenges.

AI is rapidly revolutionising industries worldwide, with healthcare being one of the primary beneficiaries of its advancements. AI offers trailblazing potential in pharmacy, particularly in enhancing medication management and personalised patient care [1]. By integrating AI-driven technologies, pharmacists are empowered with sophisticated tools that support precise, data-driven clinical decisions [4]. Through AI algorithms and machine

learning, pharmacists can now analyze vast datasets—encompassing medical records, laboratory results, and medication histories—to serve patients' individual needs better.

Pharmacists have evolved from traditional roles focused on dispensing medications to becoming integral members of healthcare teams in clinical and community settings. They ensure the safe and effective use of drugs, optimize patient outcomes, and improve healthcare quality. Their responsibilities include managing medications, educating patients on safe use, advising on drug interactions and contraindications, and coordinating care for chronic disease management. By building long-term partnerships with patients and addressing ongoing medication needs, pharmacists play a critical role in enhancing treatment outcomes and overall healthcare delivery [6,7].

Pharmacists also play a significant role in patient education, guiding disease management, medication adherence, and lifestyle modifications. This educational role is essential for promoting medication compliance and improving health outcomes [6]. In community settings, pharmacists are often patients' first point of contact, offering accessible healthcare advice and services. They engage in health promotion activities, such as screening for chronic diseases and providing immunizations [8]. Additionally, clinical pharmacists enhance patient care by collaborating with healthcare teams to develop and implement treatment plans tailored to individual needs, ensuring optimal drug therapy outcomes [9].

### *3.2. A Review of Previous Studies*

Integrating AI into pharmacy practice and drug discovery is a rapidly growing area of research. Numerous studies have highlighted its potential to enhance medication management, drug development, and personalized healthcare. While the impact of AI on drug discovery has been widely studied, its application in pharmacy operations—such as improving medication adherence, advancing patient education, and supporting clinical decision-making—remains less explored. Early investigations indicate that AI can optimize pharmaceutical practices by predicting adverse drug events, enhancing medication safety, and assisting pharmacists in personalizing patient care.

However, despite these advancements, several key areas remain underexplored. For example, AI's potential to improve medication adherence and enhance patient education has not been fully realized. Studies by Kumbhar et al. [6] and Egbewande et al. [8] highlight the critical role of pharmacists in promoting medication compliance and educating patients on proper drug use. However, integrating AI to strengthen these aspects of pharmacy practice is still in its early stages. Furthermore, challenges related to adopting AI technologies in pharmacy settings—such as data privacy concerns, technological limitations, and the need for specialized training for pharmacists—have been identified as significant obstacles in multiple studies [7,9].

Integrating AI into the pharmaceutical industry has revolutionized drug discovery, development, and patient care. Some studies explore theoretical frameworks and potential applications, while others provide real-world evidence of AI's impact, such as reducing costs, accelerating processes, and improving healthcare accessibility. This text categorizes recent studies into two groups—those offering practical insights and those focusing on conceptual advancements. Tables 1 and 2 summarize these studies, detailing their objectives, insights, practical implications, and their broader impacts on the pharmaceutical industry:

- Real-life evidence Studies: Focus on measurable outcomes in cost reduction, time efficiency, and patient care improvements. These are directly applicable to pharmaceutical practices.
- Theoretical Studies: Discuss frameworks, technological advancements, and future applications, providing the groundwork for further implementation.

**Table 1.** Summary of real-life evidence studies.

| Title | Objectives | Insights | Practical Implications |
| --- | --- | --- | --- |
| AI and digital health innovation in pharmaceutical development [10] | - Explore AI's role in pharmaceutical development efficiency.<br>- Assess in silico trials for efficacy and safety. | - AI optimizes drug discovery, enhances clinical trial efficiency, and improves patient recruitment.<br>- Utilizes data analytics and in silico trials to reduce costs and accelerate therapy delivery. | - Reduces costs and time in clinical trials.<br>- Enhances healthcare accessibility for underserved populations. |
| Integration of artificial intelligence (AI) in skills-based pharmacy courses [11]. | - Evaluate current and planned AI use in pharmacy curricula.<br>- Assess AI integration in skills-based courses. | - AI integration in pharmacy education is low, with only 18% of courses currently using it, mainly via gamification.<br>- 60% of faculty plan to implement it within two years, but barriers such as unfamiliarity persist. | - Highlights low current AI integration but significant interest.<br>- Identifies barriers to implementation. |
| AI-Driven Pharmacy Practice [12]. | - Explore AI's impact on medication management and patient care.<br>- Address challenges in implementing AI in pharmacy practice. | - Optimizes medication selection, predicts adverse events, improves inventory management, and automates prescription verification.<br>- Enables personalized patient counseling. | - Enhances pharmacist workflow and patient care.<br>- Addresses ethical, privacy, and training challenges. |
| AI and digital health innovation in pharmaceutical development [10]. | - Explore the significance of AI in drug discovery.<br>- Emphasize AI's role in identifying therapeutic candidates. | - AI revolutionizes drug discovery and development through the following ways:<br>- Analyzing large datasets.<br>- Identifying drug candidates.<br>- Predicting outcomes efficiently.<br>- Streamlines trial designs and accelerates therapy delivery. | - Accelerates drug discovery and reduces costs and time.<br>- Improves medication accessibility, especially for underserved populations. |

**Table 2.** Summary of theoretical-based studies.

| Title | Objectives | Insights | Practical Implications |
| --- | --- | --- | --- |
| Artificial Intelligence (AI) Applications in Drug Discovery [13] | - Overview of AI applications in the pharmaceutical industry.<br>- Analyze current research trends and case studies. | - Utilizes machine learning and deep learning to achieve the following:<br>- Enhance drug discovery.<br>- Optimize treatment regimens.<br>- Improve patient outcomes.<br>- Revolutionizes personalized medicine and supply chain optimization. | - Enhances efficiency and reduces costs in drug development.<br>- Advances personalized medicine approaches. |
| Artificial Intelligence: Future Aspects in the Pharmaceutical Industry [14]. | - Explore AI applications in drug discovery and development.<br>- Analyze AI's impact on personalized medicine and patient outcomes. | - Analyzes vast biological datasets and predicts drug interactions.<br>- Streamlines research processes and reduces costs.<br>- Supports personalized medicine initiatives. | - Enhances drug discovery efficiency and success rates.<br>- Reduces development costs and animal testing needs. |
| Assessing the Impact of AI: The Case of the Pharmaceutical Industry [15]. | - Explore AI's implications for the pharmaceutical industry's transformations.<br>- Address challenges in AI adoption and data management. | - Improves manufacturing processes and enhances drug discovery.<br>- Enables personalized medicine.<br>- Reshapes business models and increases efficiency. | - Enhances efficiency in drug discovery and manufacturing.<br>- Addresses challenges like IT infrastructure. |
| Artificial Intelligence in Drug Discovery and Delivery [16]. | - Explore AI applications in pharmaceutical drug discovery processes.<br>- Analyze challenges and advancements in AI/ML techniques. | - Enhances efficiency and cost-effectiveness through the following ways:<br>• Predicting biological activity and toxicity early.<br>• Aiding in hit identification and drug repurposing.<br>- Reduces failure rates in clinical trials. | - Improves efficiency in drug discovery.<br>- Optimizes drug interactions. |
| Development of Drug Discovery Platforms Using AI [17]. | - Focus on AI for small-molecule drug discovery.<br>- Discuss applications of AI in academic drug discovery. | - Enables small-molecule design, activity prediction, and 3D structure prediction of proteins.<br>- Facilitates various applications in academic drug discovery and improves efficiency. | - Enhances small-molecule drug discovery processes.<br>- Supports molecular design and activity prediction. |

Studies Presenting Real-Life Evidence

These studies provide practical insights into AI implementation and outcomes in real-world pharmaceutical scenarios.

Real-Life Evidence Studies

These studies provide practical insights into the application and outcomes of AI in pharmaceutical scenarios.

Theoretical Studies

These studies focus on frameworks, technological advancements, and potential applications of AI without real-world implementation.

## 4. Applications of Artificial Intelligence in Pharmacy

AI is revolutionizing the pharmaceutical industry, transforming key processes such as drug discovery, clinical trials, personalized medicine, manufacturing, and data management. By integrating AI into these areas, the industry is enhancing efficiency, reducing costs, and improving patient outcomes. AI's applications range from drug discovery and development to optimization, which provides unparalleled accuracy, to optimizing clinical trials, enabling personalized treatments tailored to individual needs. In personalized medicine, AI advances precision medicine strategies, revolutionizing how therapies are designed and implemented. Furthermore, AI-driven pharmaceutical manufacturing ensures process optimization and quality consistency, while in data management and analysis, it minimizes human error and improves decision-making accuracy. Together, these innovations highlight AI's pivotal role in accelerating pharmaceutical advancements, enhancing patient care, and driving operational efficiency across the sector.

### *4.1. The Role of AI and Clinical Trials in Drug Discovery and Development*

AI is revolutionizing drug discovery and clinical trials, driving vital changes that streamline and enhance the drug development process. By leveraging big data and AI, the development of smart, intelligent, innovative pharmacy practices is reshaping the discovery of chemical, biological, therapeutic, and radiological drugs, addressing the traditionally high-risk, long-term, and costly nature of drug development traditionally high-risk, long-term, and costly. Key advancements include clinical trial optimization, automation in drug discovery, cost reduction, and improved patient recruitment. Together, these innovations are accelerating medical breakthroughs, reducing costs, and improving efficiency across various stages of drug development [18,19].

#### 4.1.1. Enhancing Efficiency Across the Drug Lifecycle

As illustrated in Figure 2, AI integration is revolutionizing the drug development process by optimizing every stage—from discovery to post-market surveillance. Here is how these advancements align with the provided image:

1. Discovery and Development

AI facilitates the identification of potential drug candidates by analyzing extensive datasets of chemical compounds and predicting their efficacy. This process is complemented by AI's ability to repurpose existing drugs for new therapeutic applications, accelerating the initial stages of development [20].

2. Pre-Clinical Research

Through simulations of biological processes, AI reduces the reliance on animal models, speeding up the pre-clinical phase. Additionally, AI analyzes pre-clinical data for safety and toxicity predictions, ensuring faster and more accurate testing outcomes.




**Figure 2.** The role of AI in the drug discovery and development cycle.

3. Manufacturing

AI monitors and optimizes production processes, ensuring consistent drug quality while predicting maintenance needs for manufacturing equipment. These advancements minimize downtime, promoting efficiency and reliability in production.

4. Supply Chain Management

AI significantly enhances supply chain operations in the pharmaceutical industry by providing advanced solutions that improve efficiency and responsiveness. AI technologies, such as predictive analytics and machine learning, enable better demand forecasting, inventory optimization, and real-time disruption management, which are crucial for navigating the complexities of pharmaceutical supply chains. The following sections elaborate on these capabilities.

- Demand Forecasting
  - AI-driven predictive analytics improve demand forecasting accuracy, allowing pharmaceutical companies to anticipate fluctuations in demand more effectively [21].
  - Enhanced forecasting reduces the risks of stockouts and surplus inventory, leading to better resource allocation and customer satisfaction [22].
- Inventory Optimization
  - AI technologies optimize inventory management by analyzing data to maintain optimal stock levels, thus minimizing holding costs and ensuring compliance with regulatory requirements [23].
  - Machine learning algorithms can identify patterns in inventory usage, enabling proactive adjustments to stock levels [24].
- Real-Time Disruption Management

- AI enhances real-time visibility across the supply chain, allowing organizations to respond swiftly to disruptions and maintain operational continuity [22].
- Automation and robotics reduce human error and streamline processes, increasing resilience against supply chain disruptions [25].

5. Post-Market Surveillance

AI's analytical capabilities extend into monitoring adverse drug reactions through patient data and healthcare system reports. This includes tracking emerging safety concerns on social media platforms and ensuring a robust and proactive post-market strategy.

Figure 2 illustrates the role of AI in enhancing drug discovery and development processes.

#### 4.1.2. Clinical Trial Optimization Through AI

AI transforms clinical trials by streamlining patient recruitment, monitoring, and biomarker identification processes. Through predictive analytics, AI leverages historical data to optimize trial designs, including determining appropriate dosages and patient cohorts. This enables faster and more accurate outcomes while significantly reducing costs and time [26].

##### Patient Recruitment and Retention

AI-powered tools analyze electronic health records (EHRs) to identify eligible candidates, drastically cutting down on labor and time. Predictive models that stratify patients based on genetic and clinical data enhance participant selection and improve trial outcomes [27].

Example: In age-related macular degeneration trials, AI applications identified suitable patients with higher precision than manual methods.

##### Trial Design and Monitoring

AI enables innovative trial designs and real-time protocol adjustments through continuous data analysis. AI-driven monitoring ensures timely interventions, optimizing trial outcomes [18,19].

##### Cost and Time Efficiency

Simulations and predictive models minimize the need for experimental trials, accelerating drug development and significantly reducing physical testing costs [26].

##### Biomarker Identification

AI transforms clinical trials by streamlining key processes, including patient recruitment, monitoring, and biomarker identification. Leveraging historical data through predictive analytics optimizes trial designs, such as determining appropriate dosages and patient cohorts. These advancements enable faster and more accurate outcomes while significantly reducing the costs and time required for clinical trials [26,28].

#### 4.1.3. Automation and Data Integration in Drug Discovery

AI is revolutionizing drug discovery by automating processes and integrating data from various sources, including lab experiments, clinical trials, and patient records.

##### Data Integration

AI uncovers trends and correlations in vast datasets, providing actionable insights that traditional methods often overlook [18].

Automation

Tasks like data entry and molecular modelling are automated, allowing researchers to focus on innovation and complex problem-solving [29].

### *4.2. Reducing Labor and Development Costs*

Drug formulation has traditionally relied on labor-intensive experimentation. By analyzing molecular properties, AI models can predict effective formulations, minimizing the need for trial-and-error methods and significantly accelerating the development of new therapies [30].

#### 4.2.1. AI-Driven Patient Recruitment

Patient recruitment is a resource-intensive but crucial aspect of clinical trials. AI enhances this phase by automating tasks and improving precision.

- Efficiency in Screening

AI tools employing Natural Language Processing (NLP) and machine learning analyze unstructured EHR data to rapidly match patients to trial criteria, reducing manual effort [30,31].

- Cost and Time Savings

Automation decreases reliance on human labor, while adaptive trial designs improve resource allocation, cutting costs and expediting trials [18,26].

- Improved Accuracy

AI minimizes errors in patient selection, ensuring that only suitable candidates are enrolled [32].

#### 4.2.2. How Big Pharma Companies Are Utilizing AI in Drug Discovery

The pharmaceutical industry embraces AI as major companies integrate advanced technologies to transform drug discovery, clinical trials, and manufacturing. Figure 3 illustrates how leading firms collaborate with AI innovators to improve efficiency, cut costs, and accelerate the development of new therapies. These partnerships drive innovation and address key challenges, including patient recruitment, disease diagnosis, and treatment accessibility. Companies like Sanofi, Pfizer, and Novartis are at the forefront of this transformation, embedding AI into their core processes.

From Sanofi's development of the "Plai" AI platform for drug development to Pfizer's use of IBM's AI technology for COVID-19 treatments like Paxlovid, AI is being applied across the pharmaceutical industry in diverse ways. Companies such as AstraZeneca, Bristol Myers Squibb, and Bayer leverage AI for small molecule drug discovery and efficient clinical trial matching. At the same time, Novartis and Janssen focus on improving health outcomes and optimizing manufacturing processes. These collaborations between major pharmaceutical firms and AI innovators highlight the transformative role of AI in developing groundbreaking therapies and fostering a patient-centered approach to healthcare [33].




**Figure 3.** How big pharma companies use AI for drug discovery [33].

### *4.3. AI in Patient Care*

AI transforms patient care by enhancing diagnostic accuracy and advancing healthcare outcomes. Using sophisticated algorithms to analyze large datasets, AI enables more precise diagnoses and personalized treatment plans. This integration fosters early disease detection, efficient patient management, and optimized therapeutic strategies, revolutionizing traditional healthcare. Below are key ways AI is driving advancements in patient care.

#### 4.3.1. Enhancing Diagnostic Precision

AI-based tools, particularly in areas such as medical imaging and genomic analysis, outperform traditional diagnostic methods. These systems excel in interpreting medical scans to identify diseases like cancer and heart conditions earlier and more accurately [34]. By reducing the likelihood of human error, AI systems support clinicians in making better-informed decisions, which ultimately leads to improved patient outcomes [35]. This ability to process complex datasets quickly and effectively positions AI as critical in advancing diagnostic practices.

#### 4.3.2. Advancing Personalized Treatments

AI leverages patient-specific information, including genetic data, medical history, and lifestyle details, to create customized treatment plans. This individualized approach enhances the effectiveness of therapies while minimizing side effects, making it easier for patients to adhere to prescribed treatments [36]. Additionally, AI-powered predictive models can identify individuals at high risk for specific illnesses, allowing for preventive measures that promote population health and reduce long-term healthcare costs [37].

#### 4.3.3. Optimizing Patient Management and Care Outcomes

AI in patient management leverages predictive analytics and real-time monitoring to streamline therapeutic interventions and enhance patient care [38]. AI-driven platforms improve collaboration among healthcare providers, ensuring patients receive consistent and continuous care. This integration reduces diagnostic errors, improves treatment coordination, and enhances health outcomes [13].

### *4.4. AI in Pharmacy Operation*

AI is transforming pharmacy practices by introducing advanced capabilities that improve efficiency, accuracy, and patient care. By analyzing extensive datasets, predicting trends, and autonomously executing complex processes, AI enables pharmacies to meet the demands of modern healthcare better. This innovative technology is driving advancements in inventory management, automated dispensing, and decision-making support, reshaping the pharmaceutical landscape.

#### 4.4.1. Inventory Management

AI-driven solutions redefine pharmacy inventory management, ensuring stock levels align with real-time demand while reducing inefficiencies and waste.

- Accurate Forecasting: Machine learning algorithms analyze vast datasets, including historical sales patterns, seasonal trends, and market fluctuations, to accurately predict inventory needs. This precision helps prevent overstocking and product expiration, ensuring essential medications remain readily available [39].
- Automation of Reordering: AI integrates seamlessly with supply chain systems, automating the reordering process and reducing manual interventions. By processing real-time inventory data, these systems can identify low stock levels and place orders promptly, preventing shortages and improving overall operational efficiency [40].
- Supply Chain Responsiveness: AI-enhanced inventory management optimizes internal operations and creates a more responsive supply chain. Pharmacies can collaborate more effectively with manufacturers and distributors, ensuring supply chain disruptions have minimal impact on patient care.

#### 4.4.2. Automated Dispensing

Integrating AI and robotics into dispensing medications transforms pharmacy workflows, delivering unparalleled accuracy and efficiency.

- Precision in Prescription Filling: Automated dispensing systems powered by AI excel at processing high volumes of prescriptions with remarkable accuracy. These systems reduce human error, ensuring patients receive the correct medications and dosages. This capability is especially valuable in busy pharmacy environments, where manual errors could have profound consequences [41].
- Increased Efficiency in High-Demand Settings: Hospitals and extensive healthcare facilities benefit significantly from AI-enabled dispensing systems capable of handling extensive prescription loads. These systems improve workflow by reducing bottlenecks and ensuring timely delivery of medications, thereby enhancing patient satisfaction [42].
- Freeing Up Pharmacist Time: By automating routine dispensing tasks, AI allows pharmacists to redirect their expertise toward more patient-centered activities, such as counselling, medication reviews, and addressing patient concerns. This shift improves the overall quality of care provided to patients.

#### 4.4.3. Enhanced Decision-Making Support

AI is becoming an indispensable tool in clinical decision-making, helping pharmacists navigate complex patient care scenarios more confidently and accurately.

- Analyzing Patient Data: AI systems process vast amounts of patient information, including medical history, allergies, and current medications, to identify potential drug–drug interactions and recommend optimal dosages. This real-time analysis significantly enhances medication safety and reduces the risk of adverse events [42].
- Personalized Medicine: AI supports personalized treatment plans by tailoring medication choices and dosages to individual patient needs. By considering genetic, environmental, and lifestyle factors, AI helps pharmacists and healthcare providers deliver more effective targeted therapies, improving patient outcomes [43].
- Streamlining Clinical Decisions: AI tools that provide evidence-based recommendations further stream the decision-making process. Pharmacists can access detailed insights and predictive analyses that guide their choices, enabling a higher standard of care and optimizing therapeutic outcomes.

AI's integration into pharmacy operations drives a profound shift in how medications are managed, dispensed, and prescribed. By automating essential processes and enhancing decision-making capabilities, AI not only improves operational efficiency but also elevates the quality of patient care. These advancements highlight the revolutionary impact of AI on modern pharmacy practices, establishing a new standard for innovation and excellence in the pharmaceutical industry.

## 5. Potential Challenges

### *5.1. Potential Challenges with AI Automation in Clinical Trial Processes*

Integrating AI automation into clinical trial processes holds immense potential for enhancing efficiency, accuracy, and patient-centricity. However, it also brings various technical, regulatory, ethical, and operational challenges. Addressing these hurdles is crucial for stakeholders aiming to effectively harness AI's full potential.

#### 5.1.1. Technical Challenges

- Data Quality and Standardization

AI systems require high-quality and diverse datasets to function optimally. A lack of standardized data formats and the need for extensive data curation can hinder AI's ability to deliver accurate insights and predictions [44].

- Interoperability

Integrating AI systems with existing clinical trial infrastructures is complex due to varying system architectures and data formats. This lack of interoperability can disrupt workflows and reduce efficiency [18].

- Explainability and Validation

Many AI models function as "black boxes", making it difficult to interpret their decision-making processes. This lack of transparency can erode trust among stakeholders, necessitating rigorous validation protocols to ensure reliability and acceptance [45].

#### 5.1.2. Regulatory Guidance

Integrating AI into clinical trials is a transformative step toward improving healthcare research efficiency, accuracy, and decision-making. However, the absence of clear and cohesive regulatory frameworks creates significant obstacles to the widespread adoption of these technologies. Below is an elaboration of the key challenges:

1 Rapid Technological Advancement

AI technologies are evolving so quickly that existing regulatory policies struggle to keep up. Traditional frameworks designed for conventional clinical trial methodologies are ill-suited to the adaptive nature of AI systems. For instance, machine learning algorithms continuously update with new data, making it difficult to comply with static regulatory approval processes [45]. The lack of clear, adaptable guidelines creates uncertainty for regulators, researchers, and industry leaders, hindering the adoption of these tools and slowing innovation.

Safety and Efficacy Concerns

One of the most significant regulatory challenges involves ensuring the safety and efficacy of AI tools in clinical trials. AI-driven decision-making systems can pose risks without thorough validation, including misdiagnosis, incorrect patient stratification, and unreliable medical advice [46]. For instance, an AI system designed to identify trial participants based on specific biomarkers might inadvertently exclude eligible patients or include ineligible ones, thereby compromising trial outcomes. These safety concerns underscore the necessity of rigorous preclinical and clinical validation protocols tailored specifically for AI tools.

Additionally, the lack of transparency in many AI systems, commonly called the "black box" problem, further complicates their assessment by regulatory bodies. The inability to fully explain how an AI system reaches its conclusions undermines trust and raises ethical concerns about accountability when errors occur.

2 The Need for Global Harmonization

The global nature of clinical trials underscores the need for harmonized regulatory standards. Currently, regulatory approaches vary significantly across countries, creating barriers to the cross-border implementation of AI technologies. For instance, while the European Union has established AI ethics and safety guidelines under the EU AI Act, other regions may lack equivalent frameworks, resulting in inconsistencies [47].

- Pharmaceutical companies and researchers face challenges navigating divergent legal requirements without harmonized regulations. These disparities can increase costs, delay trials, and limit the scalability of AI innovations. Global collaboration among regulatory bodies ensures that AI-driven clinical trials adhere to consistent ethical standards, protect participant rights, and facilitate equitable access to technological advancements.
- Ethical Considerations
- Critical concerns include ethical challenges such as data privacy, algorithmic bias, and patient consent. Ensuring AI systems do not perpetuate biases or undermine patient autonomy is crucial for ethical compliance [48].

5.1.3. Operational Challenges

- Workflow Integration

Effective implementation of AI tools requires alignment with existing clinical workflows. Misalignments between AI capabilities and clinical needs can lead to inefficiencies and resistance from healthcare providers [49].

- Stakeholder Engagement

The successful deployment of AI systems depends on the active involvement of diverse stakeholders, including clinicians, patients, and regulatory bodies. Meeting the needs and expectations of all stakeholders is essential for widespread adoption [49].

5.1.4. Challenges of AI in Addressing AMR

- Antimicrobial resistance (AMR) poses a significant global health challenge as the misuse and overuse of antibiotics continue to drive the emergence of drug-resistant pathogens. AI offers promising solutions to combat AMR through several innovative approaches. AI-powered decision-support systems can optimize antibiotic prescriptions by analyzing patient data and infection patterns, reducing unnecessary usage, and minimizing resistance development. Additionally, AI accelerates drug discovery and repurposing by screening chemical libraries and predicting compound efficacy against resistant strains, significantly reducing the time and cost associated with traditional drug development. Furthermore, AI enhances surveillance by monitoring large-scale health data to detect resistance trends and hotspots, allowing for proactive public health interventions. It also supports infection prevention efforts by providing actionable insights into hospital infection control, improving sterilization protocols, and identifying high-risk areas to curb the spread of resistant pathogens [45].
- Despite its potential, leveraging AI to address AMR presents significant challenges. AI systems require large-scale, high-quality datasets, which are often incomplete, inconsistent, or siloed, limiting their effectiveness. Algorithm bias, stemming from unrepresentative training data, may lead to inaccurate prescribing recommendations or resistance predictions. Integrating AI tools with existing healthcare systems and electronic health records (EHRs) is resource-intensive and technically challenging—additionally, the absence of standardized protocols and ethical concerns regarding data privacy and security present significant barriers. The high cost of developing and maintaining AI systems and healthcare professionals' resistance to AI reliability further complicates implementation. Moreover, the rapidly evolving nature of pathogens necessitates continuous updates to AI models, while inconsistent regulatory frameworks hinder their widespread adoption across regions. Addressing these challenges will require a multidisciplinary approach, integrating collaboration between technologists, healthcare professionals, and policymakers to ensure that AI solutions for AMR are effective and equitable [45,50].

5.1.5. Societal and Human Factors

- Trust and Acceptance

Building trust in AI systems among clinicians and patients is a critical step. Concerns about job displacement, skill loss, and potential impacts on patient-clinician relationships may hinder adoption [51].

- Education and Training

Comprehensive education and training programs are needed to equip healthcare professionals with the skills to use AI tools effectively. Understanding AI's capabilities and limitations is vital for its practical application [51]. The following figure summarizes the challenges of implementing AI in pharmaceutical applications.

Figure 4 summarizes the challenges of implementing AI in Pharmacy.




**Figure 4.** Challenges of implementing AI in pharmaceutical feilds.

### *5.2. Risks of AI Integration in Pharmacy*

While AI offers significant potential, its adoption in pharmacy is not without risks. Some of the key challenges include:

- Bias in Training Data: AI systems can unintentionally perpetuate or worsen biases present in their training data. For example, Obermeyer et al. [52] found that an AI algorithm used in healthcare was less likely to recommend care for Black patients due to skewed training data.
- Data Privacy and Security: The vast amounts of patient data required for AI systems present significant privacy risks. Breaches or misuse of these data could result in legal and ethical violations, as Yanamala & Suryadevara [53] highlighted.
- Adverse Outcomes from Automation Errors: Over-reliance on AI systems without sufficient human oversight can lead to errors in drug interactions or dosages, potentially causing patient harm [54].

Case Studies of Adverse Outcomes

- Watson for Oncology: IBM's Watson for Oncology faced criticism for delivering inaccurate or unsafe treatment recommendations due to incomplete or non-representative training data [55].
- AI in Clinical Trials: A high-profile AI-driven clinical trial failed because of inaccurate predictions of patient outcomes, resulting in wasted resources and delays in drug development [56].

Ethical Considerations and Frameworks

To ensure the ethical adoption of AI, a robust framework is essential:

- Transparency and Accountability: AI systems should incorporate mechanisms for auditing decisions to maintain transparency and accountability [57].
- Bias Mitigation Strategies: Developers must use diverse and representative datasets to reduce algorithmic biases and ensure equitable treatment recommendations [58].
- Stakeholder Engagement: Involving pharmacists, patients, and regulators in the design and implementation process fosters trust and ensures that AI aligns with ethical and operational standards [59].

Strategies for Overcoming Challenges

Collaboration among stakeholders is essential to maximize the benefits of AI in pharmacy. Key actions include:

- Standardized Data Protocols: Developing consistent data formats and ensuring interoperability across systems to facilitate seamless AI integration.

- Comprehensive Training Programs: Equipping pharmacy professionals with the knowledge and skills to effectively work alongside AI technologies.
- Validation Frameworks: Establishing rigorous methods for testing AI systems to ensure accuracy, reliability, and safety.
- Regulatory Compliance: Adapting AI applications to meet evolving regulatory standards and addressing ethical considerations in their implementation.

AI is revolutionizing pharmacy by optimizing operations, improving patient care, and driving innovation. While challenges such as data standardization, regulatory hurdles, and workforce development remain, addressing these barriers through collaboration, innovation, and strategic planning will unlock AI's full potential. The pharmacy field can achieve unprecedented efficiency and effectiveness by embracing these advancements.

## 6. Discussion

Integrating AI into pharmacy goes beyond traditional roles, fundamentally transforming processes such as clinical decision-making, personalized medicine, pharmaceutical manufacturing, and operations management. While AI's potential to enhance efficiency, accuracy, and innovation is clear, its implementation comes with significant challenges that must be addressed to realize its benefits fully.

AI technologies have proven invaluable in automating labor-intensive processes across pharmacy operations. In drug discovery, AI algorithms analyze vast datasets to identify potential drug candidates, significantly reducing both time and costs. Similarly, AI optimizes clinical trials by refining patient selection, monitoring real-time data, and predicting trial outcomes, improving efficiency and cost-effectiveness. The high costs associated with drug development are substantially mitigated through AI-driven automation of research and development tasks. By streamlining processes such as molecule screening and trial management, AI reduces reliance on labor-intensive efforts, freeing up resources and enabling pharmaceutical companies to allocate budgets more effectively. This cost-efficiency benefits companies and accelerates the availability of affordable treatments for patients. Furthermore, AI systems enhance pharmacy operations by automating prescription verification, detecting potential drug interactions, and providing personalized medication recommendations, ensuring improved patient outcomes and safety.

AI technologies are transforming patient care and pharmacy operations by enabling more personalized, accurate, and proactive approaches to treatment while improving efficiency and decision-making processes. Inpatient care, AI facilitates personalized medicine by analyzing genetic, medical, and lifestyle data to develop tailored treatment plans, reducing adverse reactions and enhancing therapeutic outcomes. AI-powered platforms optimize medication types and dosages for individual patients, improving outcomes across various conditions. Additionally, AI systems, such as virtual health assistants and reminder applications, help ensure patients adhere to their medication regimens, addressing the common issue of non-adherence in chronic disease management. These tools play a vital role in reducing hospitalizations and associated healthcare costs. Furthermore, AI-integrated wearable devices provide real-time health monitoring by tracking vital signs and other health metrics, enabling early detection of complications and timely interventions. Collectively, these advancements enhance chronic condition management and elevate overall healthcare delivery.

AI enhances accuracy and efficiency in pharmacy operations through inventory management, automated dispensing, and advanced decision support. By analyzing historical data, AI systems predict stock requirements, helping to prevent shortages, minimize waste, and reduce storage costs. Automated dispensing systems powered by AI-driven robots ensure precise medication distribution, reduce human errors, and allow pharmacists to

focus on patient care. Additionally, AI tools analyze patient histories, drug interactions, and dosage requirements, enabling pharmacists to provide safer and more effective care. These applications have far-reaching benefits, including reducing medication errors, streamlining workflows, and accelerating service delivery.

AI offers significant advantages to pharmacy, including improved efficiency, cost savings, and enhanced patient outcomes. AI lowers operational and healthcare expenses by optimizing operations, reducing waste, and promoting medication adherence. Its data-driven insights facilitate proactive healthcare decisions, personalized treatments, and real-time monitoring, leading to better health outcomes and higher patient satisfaction.

However, implementing AI in pharmacy has several challenges that must be addressed. Key barriers include data standardization, seamless integration with existing healthcare systems, and mitigating biases in AI models caused by unrepresentative training data. Regulatory compliance is another critical hurdle, as AI applications must adhere to complex and evolving healthcare regulations to ensure patient safety and data privacy. High infrastructure costs and the need for a skilled workforce also pose logistical challenges. Additionally, ethical considerations—such as transparency, accountability, and fairness in AI decision-making—complicate the adoption process. Overcoming these obstacles will require strategic investments, robust validation frameworks, and interdisciplinary collaboration to integrate AI technologies into pharmacy practice effectively.

### *6.1. Future Directions*

As AI technology continues to evolve, its applications in pharmacy promise to revolutionize healthcare delivery and operational efficiency. By integrating advanced analytics, automation, and machine learning, AI will unlock new opportunities to optimize processes, enhance patient care, and address public health challenges—all while prioritizing ethical practices and patient-centric outcomes.

#### 6.1.1. Optimizing Supply Chain Management

AI transforms pharmacy supply chain management by leveraging predictive analytics to analyze vast datasets, including past sales, seasonal trends, and local health data. This ensures precise forecasting of medication demand, reducing stockouts and overstock situations while maintaining optimal inventory levels. Automation streamlines reordering processes by monitoring the stock in real-time and generating purchase orders as needed, saving staff time and improving medication availability. Additionally, AI evaluates supplier reliability, cost, and product quality, enabling pharmacies to maintain high-quality inventory while minimising costs and enhancing operational efficiency [4,60].

#### 6.1.2. Advancing Automated Dispensing Systems (ADSs)

AI enhances the functionality of Automated Dispensing Systems (ADSs) by improving accuracy and system optimization through machine learning. These systems can swiftly sort and label medications, predict maintenance needs, and customize dispensing based on patient-specific requirements, enabling personalized care and operational efficiency. By integrating ADSs with inventory management and electronic health records (EHRs), AI streamlines processes from prescription generation to billing. Additionally, AI cross-references dispensed medications with patient health records, adding a critical layer of safety by alerting pharmacists to potential drug interactions or allergies, significantly improving patient safety [4,61].

#### 6.1.3. Public Health Monitoring and Equity

AI's capabilities in public health monitoring allow for analyzing large-scale health data to detect trends in disease outbreaks, medication usage, and other public health

concerns. For example, AI could identify a spike in allergy symptoms in specific regions, prompting pharmacies to stock medications like antihistamines and epinephrine injectors to meet increased demand. Additionally, AI addresses health equity challenges by analyzing demographic data, socioeconomic indicators, and medical histories to identify areas with significant disparities. This supports tailored healthcare initiatives, such as educational programs or increased access to care for underserved populations, like those in regions with elevated asthma rates [4,62].

#### 6.1.4. Integration with Electronic Health Records (EHRs)

AI integration with EHR systems is poised to enhance pharmacy practices by improving data analysis and accessibility. Pharmacists can use AI tools to review patient histories efficiently, monitor medication adherence patterns, and identify potential health risks, ensuring a more proactive approach to patient care [63]. Furthermore, AI-powered chatbots and virtual health assistants engage patients by providing personalized medication advice, reminders, and educational resources. These tools improve adherence, foster better health outcomes, and enhance patient satisfaction [64].

#### 6.1.5. Professional Development and Ethical Implementation

As AI applications in pharmacies expand, continuous professional development among pharmacists is essential. Training programs focusing on AI literacy and ethical implementation will equip pharmacists to effectively utilize these tools, enabling them to meet the evolving demands of modern healthcare systems [65] (Figure 5 summarizes the future directions of AI in pharmacy.




**Figure 5.** Future directions of AI in pharmacy.

## 7. Conclusions

In conclusion, integrating AI into the pharmacy sector is reshaping the industry, bringing significant transformative advancements across drug discovery, clinical trials, personalized medicine, pharmaceutical manufacturing, and data management. AI's ability to analyze vast datasets, identify patterns, and automate complex processes holds immense promise for improving patient outcomes, reducing operational costs, and accelerating

innovation. These advancements not only enhance the efficiency of existing workflows but also pave the way for novel approaches to healthcare delivery, such as precision medicine and real-time public health monitoring.

Despite its potential, the successful implementation of AI in pharmacy faces significant challenges. Overcoming technical barriers, including data quality, standardization, and interoperability, is critical to ensuring AI-driven insights' accuracy, reliability, and applicability. Ethical considerations, such as ensuring algorithmic fairness, maintaining transparency, and safeguarding patient privacy, further complicate the integration process. Additionally, resistance to AI adoption among healthcare professionals and patients underscores the need for education and trust-building measures.

Addressing these challenges requires collaboration among industry stakeholders, regulatory bodies, healthcare providers, and technology developers. Establishing robust frameworks and guidelines is essential to standardize data usage, validate AI algorithms, and ensure ethical and legal standards compliance. By fostering interdisciplinary collaboration and prioritizing patient-centred care, the pharmacy sector can fully harness AI's potential to revolutionize healthcare. Ultimately, embracing AI will transform pharmacy operations and improve global health outcomes, ensuring more accessible, efficient, and equitable healthcare systems for the future.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Chalasani, S.H.; Syed, J.; Ramesh, M.; Patil, V.; Kumar, T.P. Artificial intelligence in the field of pharmacy practice: A literature review. *Explor. Res. Clin. Soc. Pharm.* **2023**, *12*, 100346. [CrossRef] [PubMed]
2. Grand View Research. Artificial Intelligence in Drug Discovery Market Size, Share & Trends Analysis Report by Application, by Region, and Segment Forecasts, 2022–2030. 2023. Available online: https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-drug-discovery-market (accessed on 6 January 2025).
3. Ghule, P.J.; Kale, P.A.; Kale, S.P. Ai-enhanced drug discovery and pharmaceutical development. In *Futuristic Trends in Pharmacy & Nursing*; IIP: Chikkamagaluru, India, 2024; Volume 3, Book 15; pp. 254–267.
4. Al Meslamani, A.Z. *Applications of AI in Pharmacy Practice: A Look at Hospital and Community Settings*; Taylor & Francis: Abingdon, UK, 2023; Volume 26, pp. 1081–1084.
5. Scheife, R.T.; Hines, L.E.; Boyce, R.D.; Chung, S.P.; Momper, J.D.; Sommer, C.D.; Abernethy, D.R.; Horn, J.R.; Sklar, S.J.; Wong, S.K. Consensus recommendations for systematic evaluation of drug–drug interaction evidence for clinical decision support. *Drug Saf.* **2015**, *38*, 197–206. [CrossRef]
6. Chavan, A.A.; Kumbhar, S.B.; Shinde, V.R.; Thorat, A.A.; Jadhav, P.B.; Jadhav, A.R.; Honrao, J.B.; Shaikh, S.A.; Raysing, S.D.; More, V.V. Role of pharmacist in healthcare system. *GSC Biol. Pharm. Sci.* **2023**, *24*, 36–45. [CrossRef]
7. Dodd, M.A.; Haines, S.L.; Maack, B.; Rosselli, J.L.; Sandusky, J.C.; Scott, M.A.; Shilliday, B.B. ASHP statement on the role of pharmacists in primary care. *Am. J. Health-Syst. Pharm.* **2022**, *79*, 2070–2078. [CrossRef]
8. Egbewande, O.M.; Abdulwasiu, M.A.; Yusuf, R.O.; Durojaye, A.B.; Ashimiyu-Abdulsalam, Z.I. Roles of community pharmacists in Cancer management. *Innov. Pharm.* **2022**, *13*, 6. [CrossRef] [PubMed]
9. Sulashvili, N.; Gorgaslidze, N.; Beglaryan, M.; Gabunia, L.; Chichoyan, N.; Giorgobiani, M.; Zarnadze, I.; Zarnadze, S.D. The scientific talks of essential issue, invocation, perspectives, inclinations and features of the clinical pharmacists globally. *Exp. Clin. Med. Ga.* **2022**. [CrossRef]
10. Ibikunle, O.E.; Usuemerai, P.A.; Abass, L.A.; Alemede, V.; Nwankwo, E.I.; Mbata, A.O. AI and digital health innovation in pharmaceutical development. *CSIT Res. J.* **2024**, *5*, 2301–2340. [CrossRef]
11. Cole, J.; Ruble, M.; Astle, K.; Tabulov, C.; Singleton, J.; Sunjic, K. Integration of artificial intelligence (AI) in skills-based pharmacy courses. *Pharm. Educ.* **2024**, *24*, 614–620. [CrossRef]
12. Rammal, D.S.; Alomar, M.; Palaian, S. AI-Driven pharmacy practice: Unleashing the revolutionary potential in medication management, pharmacy workflow, and patient care. *Pharm. Pract.* **2024**, *22*, 1–11. [CrossRef]
13. Serrano, D.R.; Luciano, F.C.; Anaya, B.J.; Ongoren, B.; Kara, A.; Molina, G.; Ramirez, B.I.; Sánchez-Guirales, S.A.; Simon, J.A.; Tomietto, G. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. *Pharmaceutics* **2024**, *16*, 1328. [CrossRef]

14. Bairagi, A.; Singhai, A.K.; Jain, A. Artificial Intelligence: Future Aspects in the Pharmaceutical Industry an Overview. *Asian J. Pharm. Technol.* **2024**, *14*, 237–246. [CrossRef]
15. Rakočević, T.; Markovic, M. Assessing the impact of AI: The case of the pharmaceutical industry. *Eur. J. Bus. Manag. Res.* **2024**, *9*, 70–75. [CrossRef]
16. Bharadwaj, S.; Deepika, K.; Kumar, A.; Jaiswal, S.; Miglani, S.; Singh, D.; Fartyal, P.; Kumar, R.; Singh, S.; Singh, M.P. Exploring the Artificial Intelligence and Its Impact in Pharmaceutical Sciences: Insights Toward the Horizons Where Technology Meets Tradition. *Chem. Biol. Drug Des.* **2024**, *104*, e14639. [CrossRef]
17. Kawai, K.; Karuo, Y.; Tarui, A.; Sato, K.; Kataoka, M.; Omote, M. Development of Drug Discovery Platforms Using Artificial Intelligence and Cheminformatics. *Chem. Pharm. Bull.* **2024**, *72*, 794–799. [CrossRef] [PubMed]
18. Mohammed, S. The impact of AI on clinical trial management. *Int. J. Adv. Res. Comput. Commun. Eng.* **2024**, *13*, 3. [CrossRef]
19. Xiao, L.; Zhang, Y. AI-driven smart pharmacology. *Intell. Pharm.* **2023**, *1*, 179–182. [CrossRef]
20. Mukherjee, D.; Sharma, T.K.; Lunawat, A.K.; Awasthi, A.; Kurmi, B.D.; Kumar, M.; Gupta, G.D.; Thakur, S. Advancement of Artificial Intelligence in Drug Discovery: A Comprehensive Review. *Curr. Artif. Intell.* **2024**, *03*, e29503752322569. [CrossRef]
21. Sokolovska, Z.; Ivchenko, I.; Ивченко, O. Design of an intelligent data analysis platform for pharmaceutical forecasts. *East.-Eur. J. Enterp. Technol.* **2024**, *5*, 14–27. [CrossRef]
22. Riad, M.; Naïmi, M.; Okar, C. Enhancing Supply Chain Resilience Through Artificial Intelligence: Developing a Comprehensive Conceptual Framework for AI Implementation and Supply Chain Optimization. *Logistics* **2024**, *8*, 111. [CrossRef]
23. Tong, C. An Efficient Intelligent Semi-Automated Warehouse Inventory Stocktaking System. *arXiv* **2023**. [CrossRef]
24. Ahmed, A.A.; Abdullahi, A.U.; Gital, A.Y.; Dutse, A.Y. Application of Artificial Intelligence in Supply Chain Management: A Review on Strengths and Weaknesses of Predictive Modeling Techniques. *Sci. J. Eng. Technol.* **2024**, *1*, 1–18. [CrossRef]
25. Kumar, P. AI for Optimizing Supply Chain Management. *Int. J. Sci. Technol. Eng.* **2024**, *12*, 549–560. [CrossRef]
26. Chopra, H.; Annu, A.; Shin, D.K.; Munjal, K.; Priyanka, P.; Dhama, K.; Emran, T.B. Revolutionizing clinical trials: The role of AI in accelerating medical breakthroughs. *Int. J. Surg.* **2023**, *109*, 4211–4220. [CrossRef]
27. Ismail, A.; Al-Zoubi, T.; Naqa, I.E.; Saeed, H. The role of artificial intelligence in hastening time to recruitment in clinical trials. *BJR | Open* **2023**, *5*, 20220023. [CrossRef]
28. Sanjay, K.; Gadekar, P.S.; Patil, K.R. Transforming Drug Discovery: The Impact of Artificial Intelligence and Machine Learning from Initial Screening to Clinical Trials. *Int. J. Sci. Technol. Eng.* **2024**, *12*, 503–508. [CrossRef]
29. Dezfooli, H.; Dashtizadeh, A.; Esmaeily, A.; Baradaranaghili, S. The vital role of artificial intelligence in accelerating the discovery and development of antibiotics. *Int. J. Adv. Res.* **2024**, *12*, 1223–1233. [CrossRef] [PubMed]
30. Rahmanian, M.; Fakhrahmad, S.M.; Mousavi, S.Z. Towards efficient patient recruitment for clinical trials: Application of a prompt-based learning model. *arXiv* **2024**. [CrossRef]
31. Beattie, J.; Neufeld, S.; Yang, D.; Chukwuma, C.; Gül, A.; Desai, N.B.; Jiang, S.; Dohopolski, M. Utilizing large language models for enhanced clinical trial matching: A study on automation in patient screening. *Cureus* **2024**, *16*, e60044. [CrossRef]
32. Gédor, M.; Desandes, E.; Chesnel, M.; Merlin, J.L.; Marchal, F.; Lambert, A.; Baudin, A. Development of an artificial intelligence system to improve cancer clinical trial eligibility screening. *Bull. Cancer* **2024**, *111*, 473–482. [CrossRef]
33. Buntz Ehidiamen, A.; Oladapo, K. Global regulatory frameworks for AI-driven healthcare: Challenges and opportunities. *Int. J. Health Policy Manag.* **2024**, *9*, 112–120.
34. Shao, J.; Feng, J.; Li, J.; Liang, S.; Li, W.; Wang, C. Novel tools for early diagnosis and precision treatment based on artificial intelligence. *Chin. Med. J. Pulm. Crit. Care Med.* **2023**, *1*, 148–160. [CrossRef]
35. Chen, J.; Hu, Y.; Wang, Y.; Lu, Y.; Cao, X.; Lin, M.; Xu, H.; Wu, J.; Xiao, C.; Sun, J. TrialBench: Multi-modal artificial intelligence-ready clinical trial datasets. *arXiv* **2024**. [CrossRef]
36. Mulukuntla, S.; Pamulaparthyvenkata, S. AI-Driven personalized medicine: Assessing the impact of federal policieson advancing patient-centric care. *EPH Int. J. Med. Health Sci.* **2020**, *6*, 20–26. [CrossRef]
37. Adeoye, S.; Adams, R. Leveraging Artificial Intelligence for Predictive Healthcare: A Data-Driven Approach to Early Diagnosis and Personalized Treatment. *Cogniz. J. Multidiscip. Stud.* **2024**, *4*, 80–97. [CrossRef]
38. Pattyam, S.P. AI in Data Science for Healthcare: Advanced Techniques for Disease Prediction, Treatment Optimization, and Patient Management. *Distrib. Learn. Broad Appl. Sci. Res.* **2019**, *5*, 417–455.
39. Mohapatra, M.; Sahu, C.; Mohapatra, S. Trends of Artificial Intelligence (AI) Use in Drug Targets, Discovery and Development: Current Status and Future Perspectives. *Curr. Drug Targets* **2024**, *26*, 221–242. [CrossRef]
40. Singh, N.; Kumar, S.; Prabhu, K.; Shukla, A.; Yadav, A. A review on: Artificial intelligence in pharma. *Int. J. Pharm. Sci. Rev. Res.* **2024**, *84*, 6. [CrossRef]
41. Stasevych, M.; Zvarych, V. Innovative robotic technologies and artificial intelligence in pharmacy and medicine: Paving the way for the future of health care—A review. *Big Data Cogn. Comput.* **2023**, *7*, 147. [CrossRef]
42. González-Pérez, Y.; Delgado, A.M.; Sesmero, J.M.M. Introducing artificial intelligence to hospital pharmacy departments. *Farm. Hosp.* **2024**, *48*, 456–462. [CrossRef] [PubMed]

43. Raymond, L.F.; Esha, S.; Martin, M.; Maria, G.; Serguei, V.S.P. Everyday Living Artificial Intelligence Hub. In *Proceedings of the Second Workshop on Data Science with Human in the Loop: Language Advances*; Association for Computational Linguistics: Stroudsburg, PA, USA, 2021; pp. 102–104. [CrossRef]
44. Gupta, D.; Wal, P.; Wal, A.R.S.; Kumar, M.; Panda, K.C.; Sharma, M.C. AI in Clinical Trials and Drug Development: Challenges and Potential Advancements. *Curr. Drug Discov. Technol.* **2024**, *22*, e15701638314252. [CrossRef]
45. Li, Y.; Cui, X.; Yang, X.; Liu, G.; Zhang, J. Artificial intelligence in predicting pathogenic microorganisms' antimicrobial resistance: Challenges, progress, and prospects. *Front. Cell. Infect. Microbiol.* **2024**, *14*, 1482186. [CrossRef] [PubMed] [PubMed Central]
46. Lee, A.; Purcell, R.; Steele, S.J. Advancing an agile regulatory ecosystem to respond to the rapid development of innovative technologies. *Clin. Transl. Sci.* **2022**, *15*, 1332–1339. [CrossRef]
47. Palaniappan, K.; Lin, E.Y.T.; Vogel, S. Global Regulatory Frameworks for the Use of Artificial Intelligence (AI) in the Healthcare Services Sector. *Healthcare* **2024**, *12*, 562. [CrossRef] [PubMed] [PubMed Central]
48. Samarth, K.; Bishnu, T.; Priyanka, D.; Asit, K.D. A Comparative Study on Various Text Classification Methods. In *Computational Intelligence in Pattern Recognition*; Springer: Berlin/Heidelberg, Germany, 2019. Available online: https://link.springer.com/chapter/10.1007/978-981-15-2449-3_46 (accessed on 6 January 2025).
49. Owoyemi, A.; Okpara, E.; Okor, M.; Awais, F.; Harwani, S.; Salwei, M.E.; Boyd, A. Lessons for Approaching Implementation of AI Systems in Clinical Settings. In Proceedings of the 2024 International Conference on Healthcare Informatics (ICHI), Orlando, FL, USA, 3–6 June 2024; pp. 472–477.
50. Natto, H.A.; Mahmood, A.A.R.; Thiruvengadam, S.; Vasanthi, R.K. Artificial intelligence in combating antimicrobial resistance. *IP Int. J. Med Microbiol. Trop. Dis.* **2024**, *10*, 189–195.
51. Vorm, E.S.; Combs, D.J.Y. Integrating Transparency, Trust, and Acceptance: The Intelligent Systems Technology Acceptance Model (ISTAM). *Int. J. Hum.-Comput. Interact.* **2022**, *38*, 1828–1845. [CrossRef]
52. Obermeyer, Z.; Powers, B.; Vogeli, C.; Mullainathan, S. Dissecting racial bias in an algorithm used to manage the health of populations. *Science* **2019**, *366*, 447–453. [CrossRef] [PubMed]
53. Yanamala, A.K.Y.; Suryadevara, S. Navigating data protection challenges in the era of artificial intelligence: A comprehensive review. *Rev. Intel. Artif. Med.* **2024**, *15*, 113–146.
54. Kücking, F.; Hübner, U.; Przysucha, M.; Hannemann, N.; Kutza, J.-O.; Moelleken, M.; Erfurt-Berge, C.; Dissemond, J.; Babitsch, B.; Busch, D. Automation bias in AI-decision support: Results from an empirical study. In *German Medical Data Sciences 2024*; IOS Press: Amsterdam, The Netherlands, 2024; pp. 298–304.
55. Chin, M.; Afsar-Manesh, N.; Bierman, A.; Chang, C.; Colón-Rodríguez, C.; Dullabh, P.; Duran, D.; Fair, M.; Hernandez-Boussard, T.; Hightower, M. Guiding Principles to Address the Impact of Algorithm Bias on Racial and Ethnic Disparities in Health and Health Care. *JAMA Netw Open* **2023**, *6*, e2345050. [CrossRef]
56. Stahl, B.C.; Wright, D. Ethics and privacy in AI and big data: Implementing responsible research and innovation. *IEEE Secur. Priv.* **2018**, *16*, 26–33. [CrossRef]
57. Talwandi, N.S.; Khare, S.; Thakur, P. Revolutionizing Pharmaceuticals: Harnessing Blockchain for Industry Solutions. In *Blockchain-Enabled Solutions for the Pharmaceutical Industry*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2025; pp. 19–40. [CrossRef]
58. Ueda, D.; Kakinuma, T.; Fujita, S.; Kamagata, K.; Fushimi, Y.; Ito, R.; Matsui, Y.; Nozaki, T.; Nakaura, T.; Fujima, N. Fairness of artificial intelligence in healthcare: Review and recommendations. *Jpn. J. Radiol.* **2024**, *42*, 3–15. [CrossRef] [PubMed]
59. Gude, S.; Gude, Y.S. The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. *Transl. Regul. Sci.* **2024**, *6*, 37–45. [CrossRef]
60. Bohr, A.; Memarzadeh, K. The rise of artificial intelligence in healthcare applications. In *Artificial Intelligence in Healthcare*; Elsevier: Amsterdam, The Netherlands, 2020; pp. 25–60.
61. Raza, M.A.; Aziz, S.; Noreen, M.; Saeed, A.; Anjum, I.; Ahmed, M.; Raza, S.M. Artificial intelligence (AI) in pharmacy: An overview of innovations. *Innov. Pharm.* **2022**, *13*. [CrossRef] [PubMed]
62. Venkatramanan, S.; Sadilek, A.; Fadikar, A.; Barrett, C.L.; Biggerstaff, M.; Chen, J.; Dotiwalla, X.; Eastham, P.; Gipson, B.; Higdon, D. Forecasting influenza activity using machine-learned mobility map. *Nat. Commun.* **2021**, *12*, 726. [CrossRef]
63. Stempel, K. *The Future of AI: Pharmacy Applications & Workflows*. DIS.IN.FX | The Germ Experts: 2023. Available online: https://docstation.co/ai-pharmacy/ (accessed on 6 January 2025).
64. Uspenskyi, S. Artificial Intelligence in Pharmacy: Use Cases, Examples, Challenges. 2024. Available online: https://springsapps.com/knowledge/artificial-intelligence-in-pharmacy-use-cases-examples-challenges (accessed on 6 January 2025).
65. Oswalt, R.; Candidate, P. The Role of Artificial Intelligence in Pharmacy Practice. 2023. Available online: https://www.pharmacytimes.com/view/the-role-of-artificial-intelligence-in-pharmacy-practice (accessed on 6 January 2025).